Novotech, the leading Asia Pacific biotech specialist CRO has released new market data in a report now available titled “Evolution of Clinical Trials in the Asia Pacific Region”. The report was prepared by GlobalData and confirms that “the Asia-Pacific (APAC) region was the largest contributor to the global clinical trial landscape from 2017 to 2021, accounting for more than 50% of conducted trials during the analysis period.”
In addition, the GlobalData research found that all phases of clinical trials in the region registered higher growth than both the US and the EU5.
The region registered significantly higher growth than the US and the EU5 across all analysed therapeutic areas, including CNS diseases, cardiovascular diseases, gastrointestinal diseases, and infectious diseases, the latter of which witnessed the highest growth. There was also 100% growth in oncology trials during the same period.
GlobalData analysis of this strong growth has been linked to a range of factors, including:
- site availability – particularly for oncology trials – when compared to the US and Europe
- lower operating costs
- the pharmacogenomic profile of Asian populations as a key factor that requires Phase I data in local populations.
“Add to the mix the ease of regulatory compliance as well as the high standards required, and overseas drugmakers have never been keener to access this burgeoning market,” according to GlobalData.
“Recent streamlining of drug approval by the government, guided by the National Health Commission (NHC) and National Medical Products Administration (NMPA), has also resulted in a more efficient and clear-cut drug approval system based on global standards.”
According to Yooni Kim, Vice President, Global Clinical Services Novotech: “Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes.”
“Novotech’s service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance.”
“In addition, experienced CRO operations across APAC and the US offer a unique and unparalleled suite of services for early to late phase biotech clinical research.”
Novotech has recently been benchmarked as a top 10 CRO among the world’s leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.
데이빗 제임스 (David James)
노보텍은 글로벌 실행 능력을 갖춘 아시아 태평양 중심의 선도적인 바이오텍 CRO 기업으로 국제적으로 인정받고 있습니다.
노보텍은 연구소, 임상1상 시험 기관, 약물 개발 컨설팅 서비스(DDC, Drug Development Consulting) 그리고 FDA 규제 전문성을 갖춘 임상 CRO 기업으로 1상에서부터 4상까지의 임상시험과 생물학적 동등성 시험을 포함하여 5,000건 이상의 임상 프로젝트에 참여한 경험이 있습니다. 노보텍은 아시아 태평양, 미국, 유럽에서 임상시험을 수행하고자 하는 바이오텍 고객들에게 서비스를 제공할 수 있습니다. 노보텍은 전 세계적으로 3,000명 이상의 직원과 34개의 사무실을 보유하고 있습니다.
보다 자세한 내용은 https://novotech-cro.com/contact를 통해 확인하실 수 있습니다.